Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $18.30.

Several brokerages have recently issued reports on TERN. JMP Securities reiterated a “market outperform” rating and issued a $20.00 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. William Blair reiterated a “market perform” rating on shares of Terns Pharmaceuticals in a research note on Friday. Oppenheimer boosted their price objective on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $7.50 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th.

Terns Pharmaceuticals Price Performance

NASDAQ TERN opened at $3.51 on Tuesday. The company has a market cap of $298.14 million, a P/E ratio of -2.97 and a beta of -0.30. Terns Pharmaceuticals has a 1-year low of $3.08 and a 1-year high of $11.40. The stock has a 50-day moving average of $4.01 and a two-hundred day moving average of $6.02.

Terns Pharmaceuticals (NASDAQ:TERN) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. On average, analysts anticipate that Terns Pharmaceuticals will post -1.19 EPS for the current fiscal year.

Insider Activity

In other news, Director Jill M. Quigley sold 8,760 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $5.79, for a total transaction of $50,720.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Emil Kuriakose sold 4,481 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.71, for a total transaction of $25,586.51. Following the completion of the transaction, the insider now directly owns 54,269 shares in the company, valued at $309,875.99. This trade represents a 7.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,669 shares of company stock worth $211,040. 15.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Terns Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Landscape Capital Management L.L.C. acquired a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth about $73,000. Townsquare Capital LLC purchased a new position in Terns Pharmaceuticals during the 4th quarter worth approximately $76,000. Sio Capital Management LLC acquired a new position in Terns Pharmaceuticals during the third quarter worth approximately $83,000. Oxford Asset Management LLP purchased a new stake in Terns Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, Savant Capital LLC acquired a new stake in shares of Terns Pharmaceuticals in the fourth quarter valued at approximately $89,000. 98.26% of the stock is owned by hedge funds and other institutional investors.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.